American Journal of Medical Case Reports
ISSN (Print): 2374-2151 ISSN (Online): 2374-216X Website: http://www.sciepub.com/journal/ajmcr Editor-in-chief: Apply for this position
Open Access
Journal Browser
Go
American Journal of Medical Case Reports. 2019, 7(2), 22-23
DOI: 10.12691/ajmcr-7-2-2
Open AccessLetter To Editor

Complete Disappearance of Numerous Hepatic and Adrenal Metastases after One Dose of Pembrolizumab in a Patient with Metastatic Malignant Melanoma

Muhammad Zubair Afzal1, and Keisuke Shirai2

1Hospital Medicine, Dartmouth-Hitchcock Medical Center, One Medical Center Dr. Lebanon, NH, 03756

2Hematology-Oncology, Norris Cotton Cancer Center, One Medical Center Dr. Lebanon, NH, 03756

Pub. Date: February 10, 2019

Cite this paper:
Muhammad Zubair Afzal and Keisuke Shirai. Complete Disappearance of Numerous Hepatic and Adrenal Metastases after One Dose of Pembrolizumab in a Patient with Metastatic Malignant Melanoma. American Journal of Medical Case Reports. 2019; 7(2):22-23. doi: 10.12691/ajmcr-7-2-2

Abstract

Although pembrolizumab is the mainstay treatment in metastatic malignant melanoma and have shown a durable response. Heterogeneous or no response has been observed in 30-40% of the cases of metastatic malignant melanoma. Metastatic lung lesions are sensitive to checkpoint inhibitor therapy whereas liver and adrenal metastases show a variable response. We are reporting a case of malignant melanoma with numerous liver and adrenal metastases showing a significant and durable response to just a single dose of pembrolizumab.

Keywords:
metastatic malignant melanoma pembrolizumab adrenal metastasis hepatic metastasis

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]  Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer. New England Journal of Medicine, 2015; 372(21), 2018-2028.
 
[2]  Wang DY, Salem J, Cohen JV. Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors. JAMA Oncology. 2018.
 
[3]  Ribas A, Hamid O, Daud A, et al. Association of pembrolizumab with tumor response and survival among patients with advanced melanoma. JAMA 2016; 315: 1600-1609.
 
[4]  Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015; 372: 2521-2532.
 
[5]  Khoja L, Kibrio M, Metser U, et al. Patterns of response to anti-PD-1 treatment: an exploratory comparison of four radiological response criteria and associations with overall survival in metastatic melanoma patients. Br J Cancer 2016; 115: 1186-1192.
 
[6]  Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014; 515: 568-571.
 
[7]  Nguyen MC, Shah MH, Liebner DA, et al. The Adrenal Gland as a Sanctuary Site of Metastases After Pembrolizumab Treatment: A Case Series. Journal of the National Comprehensive Cancer Network, 2018; 16(11), 1279-1283.